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Abstract 
Background: Trastuzumab is a monoclonal antibody that is used in treatment of breast cancer. We labeled this 
monoclonal antibody with Technetium-99m and performed in vitro and in vivo quality control tests as a first step in 
the production of a new radiopharmaceutical. 
Materials and Methods: Trastuzumab was labeled with Technetium-99m using Succinimidyl Hydrazinonicotinamide 
(HYNIC) as a chelator. Radiochemical Purity and stability in buffer and serum were determined. Immunoreactivity 
and toxicity of the complex were tested on SKBR3, MCF7 and A431 breast cancer cell lines. Biodistribution study 
was performed in normal mice at 4 and 24 h post injection. 
Results: The radiochemical purity of the complex was 95±1.4%. The stabilities in phosphate buffer and in human 
blood serum at 24 h post preparation were 85±3.5% and 74±1.2%, respectively. The immunoreactivity of the 
complex was 86±1.4%. The binding of labeled antibody to the surface of SKBR3, MCF7 and A431 cells were 
increased by increasing the human epithelial growth factor receptor 2 (Her2) concentration on the cells surface. 
Conclusion: These findings showed that the new radiopharmaceutical can be a promising candidate as Her2 antigen 
scanning for human breast cancer. 
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HER2/neu is an Mr=185 kDa transmembrane 
receptor tyrosine kinase (RTK)
1
 that has been 
extensively studied with regard to its involvement 
in cancer and as a therapeutic target in tumors. In 
breast cancer, about 25–30% of patients 
overexpress HER2/neu
2
 mainly due to gene 
amplification and in these patients, HER2/neu 
positivity is an independent prognostic indicator 
of poor long-term survival
2
.  
HER2 is poorly expressed in normal tissue, 
including normal breast. HER2 plays an 
important role in the regulation of cell cycle, 
pathogenesis and biological aggressiveness of 
breast cancers
2
. The development of monoclonal 
antibodies directed to the HER2 receptor 
extracellular domain, such as Trastuzumab, is 
currently being used for the treatment of breast 
cancer with HER2 over-expression
3,4
. 
Radioimmunoimaging of breast cancer, exploiting 
HER2/neu expression, could allow direct 
assessment of the HER2/neu status of primary and 
metastatic lesions, and may prove to be useful for 
selecting patients for treatment with trastuzumab, 
as well as predicting response to the drug
5
.  
The aim of this study was labeled 
99m
Tc with 
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Trastuzumab throughout HYNIC (Succinimidyl 
Hydrazinonicotinamide) for using as a potential 
radiopharmaceutical for in vivo minimally 
invasive evaluation of HER2 receptor expression 
in breast cancer. 
Methods 
Materials: Trastuzumab was purchased in 140 
mg vials (Genentech, South San Francisco). 
HYNIC was prepared from Solulink Co. All the 
chemicals were purchased from Fluka chemical 
corp. 
Cell line: SKBr3 (hormone-independent cells 
originally derived from a breast adenocarcinoma 
expressing high level of HER2), MCF7 (an 
estrogen-dependent mammary adenocarcinoma 
cells expressing medium level of HER2) and 
A431 (a Human epithelial carcinoma cells 
expressing low level of HER2) cell lines were 
obtained from Pasteur Institute of Iran. 
The cell lines were cultured and maintained in 
DMEM/F12 (Dulbecco's Modified Eagle 
Medium: Nutrient Mixture F-12) supplemented 
with 10% fetal bovine serum (FBS), 2mM 
glutamine, 100 units/ml penicillin and 100 µg/ml 
streptomycin in a humidified atmosphere (95% 
air and 5% CO2) at 37°C. 
The HYNIC conjugate with Trastuzumab: The 
conjugation of the HYNIC with trastuzumab was 
performed using the methods described by Abrams 
with some modifications
6
. HYNIC (a 20 M excess 
to mab, 10 mg/mL in DMF) was added dropwise to 
the mab solution (1 mg/mL in 0.15M Carbonate 
buffer, pH 8.5). The solution was stirred gently for 5 
h at room temperature protected from the light. The 
HYNIC-Trastuzumab conjugate was dialyzed 
against 0.15 M Na/acetate buffer (pH 5.2) 
overnight. 
The labeling of HYNIC-Trastuzumab with 
99m





Tc [Tricine]2 was 
then added to the solution of HYNIC-
Trastuzumab (740 MBq per each mg Ab), and the 
mixture was incubated for 1 h at room 
temperature. 
Quality control: The HYNIC-conjugated 
Trastuzumab was measured base on determination 
of hydrazide groups
8
. The radiochemical purity was 
determined by the instant thin-layer 
chromatography (ITLC). Free 
99m
Tc migrates along 
the solvent front while 
99m
Tc- HYNIC-
Trastuzumab complex remained at the origin. 
Immunoreactivity of complex was performed 
according to Lindmo method
9
. 
The stability of the labeled antibody in phosphate 
buffer saline (pH 7.4) at room temperature was 
assessed in time intervals up to 24h and was 
assessed same as the procedure described above 
by ITLC. For estimate the stability of the 
99m
Tc-
HYNIC-Trastuzumab complex in 37°C, fresh 
human serum after 24h. The labeled antibody was 
added at the concentration of 10μg/ml in serum 
and analyzed by ITLC. 
MTT assay: The cytotoxicity of the complex was 
analyzed on the SKBR3, MCF7 and A431 cell 
lines by colorimetric assay based on MTT assay
10
. 
Cell-binding assay: The SKBR3, MCF7 and 
A431 cell samples (1.0×10
6
 cells/well) were 
seeded for 24h. 
99m
Tc- HYNIC-Trastuzumab at 
concentrations of 0-100ng was added to the 
samples and incubated for 1 h at 37ºC. The 
medium was then aspirated and the cells were 
counted for 
99m
Tc radioactivity using a γ-counter. 
Biodistribution: The in vivo behavior of 
99m
Tc- 
HYNIC-Trastuzumab was evaluated in BALB/c 
mice weighing 20–25 g. The tissue biodistribution 
experiments were performed in two groups of six 
female BALB/c mice. The labeled antibody was 
injected via the tail vein (100μL, 30μg mab 
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equivalents to 3.7-5.5 MBq). At 4 and 24 h post 
injection, groups of mice were sacrificed by ether 
anesthesia. The vital organs were dissected and 
weighed. Activities of all samples were measured 
in a γ-counter, and organ activity was expressed 
as a mean percentage of injected doses per gram 
of tissue (%ID/g). 
Animal experiments were performed in 
compliance with the regulation of our institution 
and with generally accepted guidelines governing 
such work.  
Mice bearing Her2 tumor: The tumors were 
originally established from a murine mammary 
carcinoma in an inbred female BALB/c mouse. 
The breast tumor was produced by implantation of 
the tumor fragments (≈1 mm
3
) in the right flank of 
healthy inbred female BALB/c mice (20–25g, 8–
10 weeks old). The biodistribution study was 
performed  by the tumors  with volumes reached 7-
8mm
3
. To finding what is the reaction between 




Imaging studies: The biological behavior of 
99m
Tc- HYNIC-Trastuzumab was also ascertained 
by carrying out simultaneous scintigraphic imaging 
studies in mice bearing Her2 tumor (n=5). 
99m
Tc- 
HYNIC-Trastuzumab (3.7-5.5 MBq /0.1mL) was 
injected intravenously via the tail vein. Serial 
scintigraphic images were recorded at 4h after 
injection using a low-energy, high-resolution 
collimator (LEHR). Prior to the acquisition of 
images, the animals were anesthetized using a 
combination of xylazine hydrochloride and 
ketamine hydrochloride. All the images were 
recorded by acquiring 300 K counts per pixel in 
512×512 matrix size.  
Figure 2. The stability of the complex in phosphate buffer and 
human blood serum at different times after labeling. 
 
Figure 1. The immunoreactivity fraction shows the ability of the 
complex to bind to SKBR3 cells. 
 
Figure 3. The results of MTT colorimetric assay after 24h of 
treatment with different concentrations of the complex. 
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Statistical analysis: All statistical analyses were 
performed using SPSS 13.0. Each in vitro 
experiment was performed three times, each times 
the values from eight wells were determined and 
the final values were presented as mean±standard 
deviation (SD). The paired t-test was used to 
compare the results and p<0.05 were considered 
to indicate statistical significance. 
Results 
Quality control tests: The radiochemical purity 
of the complex was 95±1.4% at 1h after labeling. 
The results of the immunoreactivity tests are 
presented in figure 1. The immunoreactivity 
curve is the double inverse
 
plot of the total 
applied radioactivity divided by the cell bound
 
radioactivity against the inverse of the cell 
concentrations
12 
.  The equation of the linear 
curve fitted to data is Y=0.030X+1.521 (R
2
=0.97, 
p<0.05). The inverse of the intercept 
(1/1.521=86%) is the immunoreactivity
9
. The 
graph shows that the binding of 
99m
Tc to 
trastuzumab significantly affects the 
immunoreactivity of the antibody. The 
percentage of immunoreactivity was 86±1.4%. 
The stability of the complex in human blood serum 
and in phosphate buffer at 1, 2, 4, 6 and 24h is 
presented in figure 2. The complex showed good 
stability up to 24 h in both of the media. On the 
average 84±1.2% and 75±3.5% of the complex was 
stable in the phosphate buffer and in human blood 
serum at 24h, respectively. The stability of the 
complex in buffer was higher than that in human 
blood serum due to the lack of blood enzymes in 
the buffer. 
Cytotoxicity (MTT colorimetric assay): The 
cytotoxicity of the complex on the SKBR3, MCF7 
and A431 cell lines are shown in figure 3. No 
cytotoxicity at equal concentrations of 100ng of 
Figure 4. The cell-binding assay with SKBR3, MCF 7 and A431 cells 
with different concentration of 99mTc-S-HYNIC-Trastuzumab. 
 
Figure 5. Biodistribution study of 99mTc- HYNIC-trastuzumab in 
female BALB/c mice performed at 4 and 24 h post injection. 
 
Figure 6. The gamma camera images were acquired at 24 and 168 h 
after injection of 177Lu-trastuzumab. 
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complex was seen on the cells. 
Cell-binding assay: The affinity of the 
99m
Tc-
HYNIC-Trastuzumab for the target HER2 was 
determined with cell-binding assay. The binding of 
labeled antibody to the surface of SKBR3, MCF7 
and A431 cells were increased by increasing 
concentration of the Her2 on the cells surface 
(Figure 4). The ability of this complex to compete 
with complex to bind to the cell receptors showed 
specific binding of the 
99m
Tc-HYNIC-Trastuzumab 
onto the human breast cancer cell lines. 
Biodistribution: The result of the 
99m
Tc-HYNIC-
Trastuzumab biodistribution in the mice bearing 
breast tumors at 4 and 24h after IV administration, 
expressed as percentage of injected dose per gram 
of tissue (%ID/g) is shown in figure 5. 
Gamma camera imaging: The gamma camera 
images at 4h after injection of 
99m
Tc- HYNIC-
trastuzumab are shown in Figure 6. The tumor 
accumulated large amounts of 
99m
Tc. Small 
amounts of radioactivity could also be found in the 
liver area. A region of interest analysis of the tumor 
and corresponding lateral region gave a tumor to 
background ratio of 20±3.5 for 4h. 
Discussion 
It has been found that 20-30% of all breast 
cancers overexpress Her2
13
. These patients with 
HER2 overexpression are associated with a poor 
prognosis, more disease relapse, and distant 
metastasis. These patients may be candidates for 




Trastuzumab is a humanized antibody binds to 
the extracellular domain of the HER2 receptor. 
This antibody arrests the treated cells during the 
G1 phase of the cell cycle and exhibit reduced 
proliferation
1
. Unfortunately, Trastuzumab 
treatment is expensive and has been associated 
with cardiac toxicity
15
. For these reasons, it is very 
important to evaluate HER2 expression. Currently, 
it is evaluated by Fluorescence in situ 
hybridization (FISH) or immunohistochemistry 
from a biopsy sample. A minimally invasive in 
vivo characterization of the HER2 status of these 
patients would represent a qualitative advantage. 
This approach would be possible with the 
development of radiolabeled Trastuzumab.  
The strategy could provide information about 
HER2 expression, the receptor distribution and a 
whole body scan for HER2 tracing in positive 
metastasis. There are currently different strategies 
to label monoclonal antibodies with 
99m
Tc. A 
bifunctional agent widely used currently is the 
SHYNIC
16-18
. The main advantages of HYNIC as 
a bifunctional agent are high labeling efficiency, 
rapid and high yield radiolabeling
7
.  
In this study, the labeling procedure of 
99m
Tc-S-
HYNIC-Trastuzumab is achieving radiochemical 
purity higher than 95%. 
99m
Tc-HYNIC-
Trastuzumab showed in vitro stability in buffer 
(84±1.2%) and blood serum (75±3.5%) for 24h 
post-labeling, allowing enough time for managing 
controls and clinical application. 
The prepared complex showed good 
immunoreactivity (86±1.4%) no cytotoxicity and 
specific binding onto the SKBR3, MCF7 and 
A431 cells.  
In a study, trastuzumab was labeled with 
99m
Tc by 
Hynic (the radiochemical purity: 90%, stability 
was checked only in buffer: 95%, 
immunoreactivity: 66±0.8%, with no cell 
interaction checking) and the biodistribution was 
checked in mice bearing spontaneous breast tumor 
mice
19
. Their biodistribution findings in normal 
mice are similar to this study with slight 
differences. Their result of blood clearance at 24 h 
is about 5±2.5% and the liver uptake is increased 
by time (~11±2.5%). While the liver uptake of our 
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complex (7.7±1.6%) is slight lower and can 
produce the blood clearance 9.6 ±%2.2 after 24 h. 
This indicates no statistical significance (p<0.05). 
Conclusion 
From these results we can conclude that 
99m
Tc-
HYNIC-Trastuzumab may be considered for 
further evaluation in animals and possibly in 
humans as a new radiopharmaceutical for HER2 
detection in breast cancer. This has the potential 
to substitute breast biopsy methods to establish 
HER2 status and also to be used to detect HER2 
distant metastasis and evaluate Trastuzumab 
therapy response. 
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